Medtronic plc (NYSE: MDT) adds to the robust data for its IN.PACT® Admiral® drug-coated balloon (DCB)  with the presentation of both its formal cost-effectiveness analysis from the U.S. cohort of the IN.PACT SFA Trial and clinical results from the in-stent restenosis cohort data from Medtronic's IN.PACT Global Study. 

Medtronic plc (NYSE: MDT) today announced new clinical data in interventional treatments for aortic and peripheral vascular diseases in a late-breaking trial session at Vascular Interventional Advances (VIVA) 2015.

Three major cardiology societies released a new guideline on Sept. 23 to manage adults with all types of supraventricular tachycardia (SVT) other than atrial fibrillation.

The Heart Rhythm Society focused on the latest developments in electrophysiology and the management of patients with rhythm disorders and heart failure at its 2015 meeting on May 13-16 in Boston. The event included 12 late-breaking clinical trials.

At the American Society of Echocardiography (ASE) annual scientific sessions, the use of point-of-care echocardiography is among the major topics of discussion. The conference takes place from June 12 to June 16 at the Hynes Convention Center in Boston.

Thoratec Corporation, a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced that the FDA has granted conditional approval for a U.S. IDE clinical trial to investigate use of the HeartMate PHP acute catheter-based heart pump in patients undergoing a high-risk percutaneous coronary intervention.

Are Riata concerns a thing of the past and transcatheter aortic valve replacement (TAVR) for almost anyone with severe aortic stenosis the way of the future? Presentations at recent cardiology conferences addressed those questions.

Edwards Lifesciences put enrollment into a program using its FORTIS transcatheter valve replacement therapy on hold, announcing that it wants to investigate reports of valve thrombus.